Occudo Quantitative Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,788	Closed	-$231K	–	678
2025 Q2	$231K	Buy	+25,788	New	+$240K	0.03%	520
2024 Q1	–	Sell	-27,022	Closed	-$162K	–	743
2023 Q4	$162K	Buy	+27,022	New	+$157K	0.02%	673
2023 Q3	–	Sell	-19,110	Closed	-$135K	–	985
2023 Q2	$135K	Buy	+19,110	New	+$153K	0.01%	900
2022 Q4	–	Sell	-61,459	Closed	-$774K	–	974
2022 Q3	$774K	Buy	+61,459	New	+$791K	0.06%	512
2021 Q1	–	Sell	-87,019	Closed	-$648K	–	755
2020 Q4	$648K	Buy	+87,019	New	+$449K	0.2%	155

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's BCRX Position: Q3 2025 in Review

Occudo Quantitative Strategies sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 25,788 shares — an estimated $231K sold.

Occudo Quantitative Strategies first reported a position in BCRX in Q4 2020 and held it in 5 quarters. The position peaked at $774K in Q3 2022. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Occudo Quantitative Strategies reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Occudo Quantitative Strategies sold 25,788 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $231K.
Occudo Quantitative Strategies first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Occudo Quantitative Strategies's BioCryst Pharmaceuticals position peaked at $774K in Q3 2022.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.